Analystreport

Castle Biosciences (NASDAQ: CSTL) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $41.00 price target on the stock.

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report